DDL-218
DDL-218 is an orally active and potent SirT1 inhibitor. DDL-218 enhances SirT1 in ApoE4-expressing neurons and a murine AD model. DDL-218 can be used in the study of Alzheimer's disease[1].
Product Specifications
CAS Number
[2767324-34-3]
UNSPSC
12352005
Target
Sirtuin
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Field of Research
Neurological Disease
Purity
99.49
Smiles
N[C@@H](C)C(OC(C)(C)CC1=CC=NC=C1)=O
Molecular Formula
C12H18N2O2
Molecular Weight
222.28
References & Citations
[1]Campagna J, et al. Discovery of an ApoE4-targeted small-molecule SirT1 enhancer for the treatment of Alzheimer's disease. Sci Rep. 2025 Apr 23;15 (1) :14028.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
PB10007-Dylight488 100 µg
Anti-MAP3K8 Antibody Picoband® (Dylight488 Conjugate)
Sign In for Pricing
View Details 
K1964907 1.0 µg DNA
RPL31P48 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)
Sign In for Pricing
View Details